Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
Kamthan, A G Lind, Michael J Thatcher, Nick Steward, William P Bronchud, M H Ranson, Malcolm R Stout, Ronald
Kamthan, A G
Lind, Michael J
Thatcher, Nick
Steward, William P
Bronchud, M H
Ranson, Malcolm R
Stout, Ronald
Citations
Altmetric:
Abstract
61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease.
Description
Date
1990
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. 1990, 26 (6):691-4 Eur J Cancer